June 20, 2019

New York medical technology company receives declination letter from SEC in suspected foreign bribery case

Misonix, Inc., an ultrasonic medical devices company, announced that it had received a letter from the Securities and Exchange Commission informing the company that the SEC staff was closing its investigation with a recommendation of no enforcement action by the SEC.  The company had previously reported that it had made a voluntarily disclosure to the SEC relating to possible FCPA issues caused by the business practices of the company’s distributor in China.

Form 8-K | Misonix press release